| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
5-Propargylamino-dCTP targets DNA polymerases, serving as a substrate for DNA synthesis. The modified nucleotide is incorporated into DNA during polymerase-mediated reactions, replacing natural dCTP. The propargylamino group provides a handle for subsequent click chemistry conjugation, enabling the attachment of fluorophores, biotin, or other functional groups to the synthesized DNA.
|
|---|---|
| ln Vitro |
5-Propargylamino-dCTP demonstrates in vitro activity as a substrate for DNA polymerases in PCR, DNA labeling, and sequencing reactions. The compound is incorporated into DNA by DNA polymerases, and the propargylamino group enables subsequent click chemistry conjugation. Its activity is assessed by its ability to support DNA synthesis and labeling reactions.
|
| ln Vivo |
In vivo activity is not applicable to 5-propargylamino-dCTP as it is a chemical reagent for research use only, not a therapeutic agent. The compound is not intended for administration to living organisms.
|
| Enzyme Assay |
In vitro enzyme assays for 5-propargylamino-dCTP involve measuring its incorporation into DNA by DNA polymerases. The assay typically uses PCR or primer extension reactions with DNA polymerase, template DNA, primers, and a mixture of dNTPs including the modified nucleotide. Incorporation is assessed by detecting the modified nucleotide in the reaction products.
|
| Cell Assay |
In vitro cellular assays are not applicable to 5-propargylamino-dCTP. The compound is used exclusively in cell-free molecular biology applications such as PCR, DNA labeling, and sequencing. The compound itself is not tested directly on cells.
|
| Animal Protocol |
In vivo animal experiments are not applicable to 5-propargylamino-dCTP. The compound is a research chemical used in molecular biology applications and is not intended for in vivo administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to 5-propargylamino-dCTP as it is a research reagent, not a therapeutic agent. The compound is not intended for systemic administration.
|
| Toxicity/Toxicokinetics |
5-Propargylamino-dCTP is not intended for human therapeutic use, and toxicological data are not applicable as it is a research chemical. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
5-Propargylamino-dCTP (CAS#: 115899-39-3) has the molecular formula C12H17N4O12P3 and a molecular weight of 502.20. It is a modified nucleotide analog of dCTP containing a propargylamino group. The compound is used as a substrate for DNA polymerases in DNA labeling, sequencing, and nucleic acid detection applications. It is for research use only.
|
| Molecular Formula |
C12H19N4O13P3
|
|---|---|
| Molecular Weight |
520.22
|
| Exact Mass |
520.016
|
| CAS # |
115899-39-3
|
| PubChem CID |
11283796
|
| Appearance |
White to off-white solid powder
|
| Density |
2.2±0.1 g/cm3
|
| Boiling Point |
836.0±75.0 °C at 760 mmHg
|
| Flash Point |
459.4±37.1 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.744
|
| LogP |
-4.8
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)C#CCN)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O
|
| InChi Key |
LVTQIVFSMGDIPF-IVZWLZJFSA-N
|
| InChi Code |
InChI=1S/C12H19N4O13P3/c13-3-1-2-7-5-16(12(18)15-11(7)14)10-4-8(17)9(27-10)6-26-31(22,23)29-32(24,25)28-30(19,20)21/h5,8-10,17H,3-4,6,13H2,(H,22,23)(H,24,25)(H2,14,15,18)(H2,19,20,21)/t8-,9+,10+/m0/s1
|
| Chemical Name |
[[(2R,3S,5R)-5-[4-amino-5-(3-aminoprop-1-ynyl)-2-oxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
|
| Synonyms |
5-Propargylamino-dCTP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~480.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9223 mL | 9.6113 mL | 19.2226 mL | |
| 5 mM | 0.3845 mL | 1.9223 mL | 3.8445 mL | |
| 10 mM | 0.1922 mL | 0.9611 mL | 1.9223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
